__label__noRel	The overall remission rate was 87% with 31% complete remissions.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The overall remission rate was 87% with 31% complete remissions.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The overall remission rate was 87% with 31% complete remissions.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__Support	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__Support	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__Support	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	patients with early alternating chemotherapy achieve a better subjective adjustment,	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The overall remission rate was 87% with 31% complete remissions.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The median survival of all 406 eligible patients was 346 days with 15% of the patients alive at two years.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	The overall remission rate, the rate of complete remission, the median survival and the rate of long-term survival were not significantly different in the two treatment arms.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	In limited disease the estimated percentages of survival at 2 years were 33% in the early and 24% in the late alternating chemotherapy arms.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Patients with extensive disease survived significantly longer with late alternating chemotherapy than on the early alternation regimen (median survival 336 days versus 301 days, p = 0.01).
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	In the latter patients the received dose intensities (RDI) of cisplatin, adriamycin and etoposide were significantly higher in the late-alternation arm.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Patients treated with early alternating chemotherapy rated their tumor symptoms, functional states, fatigue/malaise and restriction of social activity significantly better, reflecting an improved subjective adjustment.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	Alternating chemotherapy with PAV-CyMOC plus consolidating radiotherapy is a feasible and effective treatment for small-cell lung cancer, with acceptable toxicity.
__label__noRel	late alternating chemotherapy allows for a higher RDI of cisplatin, adriamycin and etoposide, which results in a significantly longer median survival of patients with extensive disease.	patients with early alternating chemotherapy achieve a better subjective adjustment,
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.	CP resulted in more anastomotic leaks.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative	CP resulted in more anastomotic leaks.
__label__Support	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.	CP resulted in more anastomotic leaks.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	there were no differences in the bowel function, continence score, and quality of life at 1 year.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	there were no differences in the bowel function, continence score, and quality of life at 1 year.	CP resulted in more anastomotic leaks.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	There were no differences in the anorectal manometry and endoanal ultrasound findings.	CP resulted in more anastomotic leaks.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.	CP resulted in more anastomotic leaks.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	the J-pouch remains the benchmark for routine clinical practice,	CP resulted in more anastomotic leaks.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	due care (including defunctioning stoma) should be exercised in situations requiring CP.	CP resulted in more anastomotic leaks.
__label__noRel	CP resulted in more anastomotic leaks.	A colonic J-pouch may reduce excessive stool frequency and incontinence after anterior resection, but at the risk of evacuation problems.
__label__noRel	CP resulted in more anastomotic leaks.	Experimental surgery on pigs has suggested that a coloplasty pouch (CP) may be a useful alternative
__label__noRel	CP resulted in more anastomotic leaks.	At 4 months, J-pouch patients had 10.3% less stool fragmentation but poorer stool deferment and more nocturnal leakage.
__label__noRel	CP resulted in more anastomotic leaks.	there were no differences in the bowel function, continence score, and quality of life at 1 year.
__label__noRel	CP resulted in more anastomotic leaks.	There were no differences in the anorectal manometry and endoanal ultrasound findings.
__label__Support	CP resulted in more anastomotic leaks.	Coloplasty pouches resulted in more anastomotic leaks and minimal differences in bowel function.
__label__noRel	CP resulted in more anastomotic leaks.	the J-pouch remains the benchmark for routine clinical practice,
__label__noRel	CP resulted in more anastomotic leaks.	due care (including defunctioning stoma) should be exercised in situations requiring CP.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Median survival with GC and PE was 8.0 and 8.1 months, respectively.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Attack	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__Attack	but these were not associated with increased hospital admissions, infections or fatalities.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__noRel	but these were not associated with increased hospital admissions, infections or fatalities.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__Support	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__Support	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	There was no difference in overall survival (HR 1.01, 95% CI 0.77 to 1.32).
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Median survival with GC and PE was 8.0 and 8.1 months, respectively.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Median progression-free survival was 5.9 months with GC and 6.3 months with PE.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Grade 3 or 4 myelosuppressions were more frequent with GC (anaemia: 14% GC vs 2% PE; leucopenia: 32% GC vs 13% PE; thrombocytopenia: 22% GC vs 4% PE),
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	but these were not associated with increased hospital admissions, infections or fatalities.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	Grade 2-3 alopecia (68% PE vs 17% GC) and nausea (43% PE vs 26% GC) were more frequent with PE.
__label__noRel	GC is as effective as PE in terms of overall survival and progression-free survival and has a toxicity profile more acceptable to patients.	In QoL questionnaires, more patients receiving PE reported being upset by hair loss (p = 0.004) and impaired cognitive functioning (p = 0.04).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__Support	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	For those patients who have recurrence of disease at least 6 months after initial therapy, the paclitaxel-platinum combination has been shown to be a superior treatment to platinum monotherapy.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	However, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation.
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	With a median follow-up of 17 months, median PFS was 8.6 months for gemcitabine-carboplatin (95% confidence interval [CI] 7.9-9.7 months) and 5.8 months for carboplatin (95% CI 5.2-7.1 months; hazard ratio [HR] 0.72 [95% CI 0.58-0.90; P = 0.0032]).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	The response rate for the gemcitabine-carboplatin group was 47.2% (95% CI 39.9-54.5%) and 30.9% for carboplatin group (95% CI 24.1-37.7%; P = 0.0016).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	The HR for overall survival was 0.96 (95% CI 0.75-1.23; P = 0.7349).
__label__noRel	Gemcitabine-carboplatin treatment significantly improves the PFS of patients with platinum-sensitive recurrent ovarian cancer.	Patients treated with gemcitabine-carboplatin reported significantly faster palliation of abdominal symptoms and a significantly improved global quality of life.
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	Pilates exercises are effective and safe in female breast cancer patients.	There is a need for further studies so that its effect can be confirmed.
__label__Support	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Support	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Support	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).	There is a need for further studies so that its effect can be confirmed.
__label__Attack	There is a need for further studies so that its effect can be confirmed.	Pilates exercises are effective and safe in female breast cancer patients.
__label__noRel	There is a need for further studies so that its effect can be confirmed.	When the two exercise groups were compared, there were significant differences in 6MWT in pilates-exercise group (P<0.05).
__label__noRel	There is a need for further studies so that its effect can be confirmed.	After the exercise program, improvements were observed in Group 1 in 6-minute walk test, BDI, EORTC QLQ-C30 functional, and EORTC QLQ-C30 BR23 functional scores (P<0.05).
__label__noRel	There is a need for further studies so that its effect can be confirmed.	no significant improvement was observed in Group 2 after the exercise program in any of parameters in comparison to the pre-exercise period (P>0.05).
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__Support	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__Support	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	At 12 months post-randomisation, there was no significant difference between treatment and control groups in terms of arm volume.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	Absolute change in arm volume at 12 months was 2.5% (95% CI -0.40 to 5.3) in the treatment group compared to 1.2% (95% CI -2.8 to 5.1) in the placebo group.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	The difference in mean volume change between randomisation groups at 12 months was not statistically significant (P = 0.6), -1.3% (95% CI -6.1 to 3.5), nor was there a significant difference in response at 6 months (P = 0.7), where mean change in arm volume from baseline in the treatment and placebo groups was -2.3% (95% CI -7.9 to 3.4) and -1.1% (95% CI -3.9 to 1.7), respectively.
__label__noRel	The study fails to demonstrate efficacy of dl-alpha tocopheryl acetate plus pentoxifylline in patients with arm lymphoedema following axillary surgery and lymphatic radiotherapy, nor does it suggest any benefits of these drugs in radiation-induced induration (fibrosis) in the breast, chest wall, pectoral fold, axilla or supraclavicular fossa.	There were no significant differences between randomised groups in terms of secondary endpoints, including tissue induration (fibrosis) in the irradiated breast or chest wall, pectoral fold or supraclavicular fossa, change in photographic breast/chest wall appearance or patient self-assessment of function and Quality of Life at either 6 or 12 months.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	but there were positive changes in group A patients.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Difference between groups (p=0.007) for BMD at femur was significant.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	but there were positive changes in group A patients.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	but there were positive changes in group A patients.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	but there were positive changes in group A patients.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	but there were positive changes in group A patients.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	but there were positive changes in group A patients.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	but there were positive changes in group A patients.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	but there were positive changes in group A patients.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	but there were positive changes in group A patients.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	but there were positive changes in group A patients.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	but there were positive changes in group A patients.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	but there were positive changes in group A patients.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	but there were positive changes in group A patients.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	but there were positive changes in group A patients.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	but there were positive changes in group A patients.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	but there were positive changes in group A patients.
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	but there were positive changes in group A patients.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Difference between groups (p=0.007) for BMD at femur was significant.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The changes of BMD in group B patients were significantly greater than patients in group A (p=0.011, CI=0.063-0.437), and group C (p=0.003, CI=0.146-0.620).
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The mean BAP increased from baseline in group B patients but decreased from baseline in group C patients at 3 months and 15 months.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	No statistical significance was found in the FACT-G scores and FACT-B scores among different groups at baseline, week 4, week 8 and week 12 after NHT.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	The Breast Cancer Subscale scores in group A patients were significantly higher than that of group C patients (p=0.021).
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	After 4 weeks of NHT, negative changes of FACT-B and FACT-G scores were found in group B and C patients,
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	but there were positive changes in group A patients.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Significant differences of FACT-B score (p=0.008) and FACT-G score (p=0.019) were observed at that time point.
__label__noRel	Cyclooxygenase-2 (COX-2) inhibitors have been shown to be effective in chemoprevention in animal and clinical studies.	Anti-aromatase therapy is important in the treatment of breast cancer in postmenopausal women
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	the between-group difference was statistically significant (P<0.01).
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	the between-group difference was statistically significant (P<0.05).
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	the between-group difference was statistically significant (P<0.01).
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	the between-group difference was statistically significant (P<0.05).
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	the between-group difference was statistically significant (P<0.01).	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__Support	the between-group difference was statistically significant (P<0.01).	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.01).	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.01).	the between-group difference was statistically significant (P<0.05).
__label__noRel	the between-group difference was statistically significant (P<0.01).	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	the between-group difference was statistically significant (P<0.01).	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	the between-group difference was statistically significant (P<0.01).	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	the between-group difference was statistically significant (P<0.01).
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	the between-group difference was statistically significant (P<0.05).
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.05).	the between-group difference was statistically significant (P<0.01).
__label__Support	the between-group difference was statistically significant (P<0.05).	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	the between-group difference was statistically significant (P<0.05).	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	the between-group difference was statistically significant (P<0.05).	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	the between-group difference was statistically significant (P<0.05).	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	the between-group difference was statistically significant (P<0.01).
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	the between-group difference was statistically significant (P<0.05).
__label__noRel	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__Support	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	the between-group difference was statistically significant (P<0.01).
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	the between-group difference was statistically significant (P<0.05).
__label__noRel	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__Support	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Recent studies have shown that administering the aromatase inhibitor exemestane after 2-3 years of tamoxifen therapy significantly improves disease-free survival in postmenopausal women with primary breast cancer in comparison with standard 5-year tamoxifen treatment.
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Fat mass had significantly decreased by month 12 in the exemestane, but not in the tamoxifen group;
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	the between-group difference was statistically significant (P<0.01).
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	The FFM/FM ratio had significantly increased in the exemestane group, but not the tamoxifen group;
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	the between-group difference was statistically significant (P<0.05).
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	Triglycerides and high-density lipoprotein cholesterol significantly decreased (P<0.01; P<0.05),
__label__noRel	Our findings suggest that switching patients to adjuvant exemestane treatment after at least 2 years of tamoxifen therapy may be associated with an advantage over continuing adjuvant tamoxifen treatment in terms of body composition.	low-density lipoprotein cholesterol significantly increased (P<0.01) in the exemestane group at the end of the 1-year study period.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Most patients with advanced ovarian cancer develop recurrent disease.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Most patients with advanced ovarian cancer develop recurrent disease.
__label__Attack	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__Support	No statistically significant differences in quality of life scores between arms were noted.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	No statistically significant differences in quality of life scores between arms were noted.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	No statistically significant differences in quality of life scores between arms were noted.
__label__noRel	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Most patients with advanced ovarian cancer develop recurrent disease.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel;
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349).
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon.
__label__noRel	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	No statistically significant differences in quality of life scores between arms were noted.
__label__Support	With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin.	Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Safe, effective non-hormonal treatments are needed.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	We recorded no CBT-related adverse events.
__label__noRel	Hormone replacement therapy is often either undesirable or contraindicated.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__noRel	Safe, effective non-hormonal treatments are needed.	We recorded no CBT-related adverse events.
__label__noRel	Safe, effective non-hormonal treatments are needed.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	Safe, effective non-hormonal treatments are needed.
__label__noRel	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	We recorded no CBT-related adverse events.
__label__Support	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	We recorded no CBT-related adverse events.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	We recorded no CBT-related adverse events.	Safe, effective non-hormonal treatments are needed.
__label__noRel	We recorded no CBT-related adverse events.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__Support	We recorded no CBT-related adverse events.	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Hormone replacement therapy is often either undesirable or contraindicated.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Safe, effective non-hormonal treatments are needed.
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	Group CBT significantly reduced HFNS problem rating at 9 weeks after randomisation compared with usual care (mean difference -167, 95% CI -243 to -091; p<00001) and improvements were maintained at 26 weeks (mean difference -176, -254 to -099; p<00001).
__label__noRel	Group CBT seems to be a safe and effective treatment for women who have problematic HFNS after breast cancer treatment with additional benefits to mood, sleep, and quality of life.	We recorded no CBT-related adverse events.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	The quality of life was almost the same between the arms
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	The quality of life was almost the same between the arms
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	The quality of life was almost the same between the arms
__label__Support	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	The quality of life was almost the same between the arms
__label__noRel	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__Support	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	The quality of life was almost the same between the arms
__label__Support	Grades 3/4 toxicities occurred infrequently in both arms.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	Grades 3/4 toxicities occurred infrequently in both arms.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	The quality of life was almost the same between the arms	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	The quality of life was almost the same between the arms	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	The quality of life was almost the same between the arms	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	The quality of life was almost the same between the arms	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	The quality of life was almost the same between the arms	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	The quality of life was almost the same between the arms	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	The quality of life was almost the same between the arms	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	The quality of life was almost the same between the arms
__label__noRel	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The possible effectiveness of 5-FU+low-dose CDDP for colorectal cancer (CRC) is intriguing.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Recently, the treatment of advanced gastric cancer by continuous infusion of 5-fluorouracil (5-FU) with low-dose cisplatin (CDDP) has improved efficacy without severe toxicities.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The response rate in the 5-FU+low-dose CDDP arm (n=75) was significantly higher than that in the 5-FU arm (n=77) (25.3% vs. 11.7%; P = 0.037).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	There was no significant difference in the median overall survival time between the 5-FU+low-dose CDDP arm and the 5-FU arm (479 and 491 days, respectively).
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Grades 3/4 toxicities occurred infrequently in both arms.
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	The quality of life was almost the same between the arms
__label__noRel	However, this combined treatment did not confer a survival advantage over treatment with continuous infusion of 5-FU alone for patients with far-advanced CRC; that might be attributable to the short CDDP administration setting of 12 weeks.	Low-dose CDDP improved the response rate while keeping toxicities within clinically acceptable limits.
__label__noRel	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__Support	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__noRel	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__Support	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__Attack	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	At the post-treatment assessment, IMCP participants demonstrated significantly greater improvement than the control condition for the primary outcomes of spiritual well-being (b = 0.39; P <.001, including both components of spiritual well-being (sense of meaning: b = 0.34; P = .003 and faith: b = 0.42; P = .03), and quality of life (b = 0.76; P = .013).
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	Significantly greater improvements for IMCP patients were also observed for the secondary outcomes of symptom burden (b = -6.56; P < .001) and symptom-related distress (b = -0.47; P < .001) but not for anxiety, depression, or hopelessness.
__label__noRel	IMCP has clear short-term benefits for spiritual suffering and quality of life in patients with advanced cancer.	At the 2-month follow-up assessment, the improvements observed for the IMCP group were no longer significantly greater than those observed for the TM group.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	No decrease in fatigue-related distress was detected.
__label__noRel	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The intervention demonstrated a trend toward improved CRF,	No decrease in fatigue-related distress was detected.
__label__Support	The intervention demonstrated a trend toward improved CRF,	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__Attack	although this effect was reduced once confounders had been controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	No decrease in fatigue-related distress was detected.
__label__noRel	although this effect was reduced once confounders had been controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	No decrease in fatigue-related distress was detected.
__label__Support	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	No decrease in fatigue-related distress was detected.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	No decrease in fatigue-related distress was detected.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	No decrease in fatigue-related distress was detected.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	No decrease in fatigue-related distress was detected.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__Support	No decrease in fatigue-related distress was detected.	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	It has been shown that nonpharmacologic interventions are effective management techniques for cancer-related fatigue (CRF) in cancer survivors.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	The intervention demonstrated a trend toward improved CRF,
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	although this effect was reduced once confounders had been controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	There was a significant improvement in physical functioning (coefficient, 10.0; 95% confidence interval, 2.5-17.5; P = .009), and this effect remained once the confounding effects of mood disturbance and comorbid disorders were controlled statistically.
__label__noRel	The behaviorally oriented intervention brought about significant improvements in physical functioning, indicated a trend toward improved CRF, but detected no effect for fatigue-related distress.	No decrease in fatigue-related distress was detected.
__label__noRel	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).
__label__noRel	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.
__label__Support	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.
__label__noRel	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.
__label__Support	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.	This research study indicates that live music therapy using patient-preferred music can be beneficial in improving quality of life indicators such as anxiety, perception of the hospitalization or procedure, relaxation, and stress in patients undergoing surgical procedures of the brain.
__label__noRel	No statistically significant differences were found for mood (p > .05) or pain (p > .05) levels.	Results indicated statistically significant differences for 4 of the 6 quality of life measures: anxiety (p = .03), perception of hospitalization (p = .03), relaxation (p = .001), and stress (p = .001).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__Attack	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__Support	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.
__label__noRel	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
__label__noRel	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	For willingness-to-pay between $5000 and $40 000 per quality-adjusted life year, the single-fraction schedule was statistically significantly more cost-effective than the multiple-fraction schedule (P< or =.05).
__label__Support	Compared with multiple-fraction radiotherapy, single-fraction radiotherapy provides equal palliation and quality of life and has lower medical and societal costs, at least in The Netherlands.	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Radiotherapy is an effective palliative treatment for cancer patients with painful bone metastases.
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	Comparing the single- and multiple-fraction radiotherapy schedules, no differences were found in life expectancy (43.0 versus 40.4 weeks, P =.20) or quality-adjusted life expectancy (17.7 versus 16.0 weeks, P =.21).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	The estimated cost of radiotherapy, including retreatments and nonmedical costs, was statistically significantly lower for the single-fraction schedule than for the multiple-fraction schedule ($2438 versus $3311, difference = $873, 95% confidence interval [CI] on the difference = $449 to $1297; P<.001).
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	The estimated difference in total societal costs was larger, also in favor of the single-fraction schedule,
__label__noRel	Therefore, single-fraction radiotherapy should be considered as the palliative treatment of choice for cancer patients with painful bone metastases.	but it was not statistically significant ($4700 versus $6453, difference = $1753, 95% CI on the difference = -$99 to $3604; P =.06).
